In an interview during the 2022 ASCO Annual Meeting, lead author Mark Fleming, MD, Virginia Oncology Associates (US Oncology Network), discussed the results of an abstract he presented that highlighted the latest findings with the PET imaging agent 18F-rhPSMA-7.3. in the phase 3 SPOTLIGHT trial.
- Key Prostate Cancer Research
- Cohort Study Identified Optimal Minimum Treatment Duration for ADT in High-Risk Prostate Cancer
- MRI-Guided HIFU Effective in Intermediate-Risk Prostate Cancer
- The Future of Metastatic Prostate Cancer Management
- Researchers Uncover Mechanism By Which Prostate Cancer Becomes Resistant